Prior therapy with anti-CD20 chimeric antibody (Rituximab) may decrease the risk of acute graft-versus-host disease (GVHD) in patients with non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.

被引：0
|
作者：
Ratanatharathorn, V
Bociek, RG
Pavletic, SZ
Lynch, JC
Ferrara, JLM
Uberti, JP
机构：
[1] Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA
[2] Univ Nebraska, Omaha, NE USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1688
引用
收藏
页码：391A / 391A
页数：1
相关论文
共 50 条
  • [41] IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with pretreated low-grade non-Hodgkin's lymphoma.
    Schwandt, KU
    Bremer, K
    ANNALS OF ONCOLOGY, 2000, 11 : 105 - 105
  • [42] Radioimmunotherapy with iodine-131 anti-CD20 chimeric monoclonal antibody (rituximab) for relapsed or refractory indolent non-Hodgkin's lymphoma: Results of an Australian phase II trial
    Leahy, MF
    Seymour, JF
    Hicks, RJ
    Turner, JH
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 156
  • [43] A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800.
    Maloney, DG
    Press, OW
    Braziel, RM
    Unger, JM
    LeBlanc, ML
    Grogan, TM
    Miller, TP
    Fisher, RI
    BLOOD, 2001, 98 (11) : 843A - 843A
  • [44] Treatment of patients with mantle cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab (Rituxan™):: Evaluation of safety and response.
    Winkler, U
    Schulz, HR
    Klein, TO
    Jensen, M
    Manzke, O
    Schmitz, SH
    Rüdiger, T
    Müller-Hermelink, KH
    Diehl, V
    Engert, A
    BLOOD, 1999, 94 (10) : 270B - 270B
  • [45] Role of Anti-Lymphocyte Globulin in Prophylaxis of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia
    Wakamatsu, Manabu
    Uchida, Naoyuki
    Ohashi, Kazuteru
    Fukuda, Takahiro
    Kanamori, Heiwa
    Ozawa, Yukiyasu
    Ichinohe, Tatsuo
    Kanda, Yoshinobu
    Murata, Makoto
    Kato, Koji
    Atsuta, Yoshiko
    Teshima, Takanori
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S71 - S71
  • [46] CD8 T cell dose impacts acute graft-versus-host disease after reduced intensity conditioning (RIC) for allogeneic stem cell transplantation.
    Mohty, M
    Faucher, C
    Bagatini, S
    Bardou, VJ
    Bilger, K
    Chabannon, C
    Ladaique, P
    Vey, N
    Maraninchi, D
    Blaise, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 590S - 590S
  • [47] Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation
    Lee, Ming-Yang
    Chiou, Tzeon-Jye
    Hsiao, Liang-Tsai
    Yang, Muh-Hwa
    Lin, Pang-Chan
    Poh, Say-Bee
    Yen, Chueh-Chuan
    Liu, Jin-Hwang
    Teng, Hao-Wei
    Chao, Ta-Chung
    Wang, Wei-Shu
    Chen, Po-Min
    ANNALS OF HEMATOLOGY, 2008, 87 (04) : 285 - 289
  • [48] Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation
    Ming-Yang Lee
    Tzeon-Jye Chiou
    Liang-Tsai Hsiao
    Muh-Hwa Yang
    Pang-Chan Lin
    Say-Bee Poh
    Chueh-Chuan Yen
    Jin-Hwang Liu
    Hao-Wei Teng
    Ta-Chung Chao
    Wei-Shu Wang
    Po-Min Chen
    Annals of Hematology, 2008, 87 (4) : 285 - 289
  • [49] Cytomegalovirus (CMV) infection in patents receiving either alemtuzumab (Campath) or antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prophylaxis prior to allogeneic stem cell transplantation (SCT)
    Hunt, WG
    Carrum, G
    Popat, U
    May, GR
    Demmler, GJ
    Krance, RA
    Heslop, HE
    Kuehnle, I
    PEDIATRIC RESEARCH, 2003, 53 (04) : 319A - 319A
  • [50] Non-HLA genetic polymorphisms influence risk of acute and chronic graft-versus-host disease, early death and infection following allogeneic haemopoietic stem cell transplantation.
    Mullighan, CG
    Heatley, S
    Doherty, K
    Szabo, F
    Grigg, AP
    Hughes, TP
    Schwarer, AP
    Szer, J
    Tait, BD
    To, LB
    Bardy, PG
    BLOOD, 2001, 98 (11) : 739A - 740A
12345